What STENTiT does

STENTiT is a Netherlands-based medical device company and spin-off from Eindhoven University of Technology that develops regenerative endovascular implants for the treatment of peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI). Its single core product, the Resorbable Fibrillated Scaffold (RFS), is a bioresorbable, strutless stent manufactured from electrospun microfibres and designed for below-the-knee (BTK) applications. Unlike permanent metallic stents, the RFS provides temporary structural support to damaged blood vessels and is intended to gradually dissolve while facilitating tissue regeneration, targeting the prevention of limb amputations in CLTI patients.

The company operates a hardware-sales business model, distributing its medical devices directly to hospitals and vascular surgery centers through traditional medical device procurement channels. STENTiT remains pre-commercial and in clinical development; as of early 2026, the VITAL-IT 1 first-in-human study conducted at the Medical University of Graz, Austria, had completed five implantations with 100% technical success and no device- or procedure-related serious adverse events at 30-day follow-up. The company is led by CEO and co-founder Bart Sanders, is headquartered in Eindhoven, Netherlands, employs 11-50 people, and is currently capitalized by a €1.8M seed round from NextGen Ventures, BOM, and Ten Cate Investment Company (April 2022).

Name

STENTiT

Legal name

STENTiT

Website

https://stentit.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

STENTiT is a Netherlands-based medical device spin-off from Eindhoven University of Technology developing a bioresorbable, strutless endovascular scaffold from electrospun microfibres to treat below-the-knee chronic limb-threatening ischemia and prevent amputations.

Ownership category

akta.pro rank

Product category

Vascular Medical Devices / Endovascular Implants

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

Keywords

• Bioresorbable vascular scaffolds
• Endovascular implants
• Peripheral artery disease devices
• Regenerative medical devices
• Chronic limb-threatening ischemia treatment

Headquarters

HQ city

Eindhoven

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: As a medical device company developing regenerative endovascular implants, STENTiT generates revenue through the sale of its bioresorbable scaffolds and implants to healthcare providers treating peripheral artery disease and chronic limb-threatening ischemia.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

STENTiT develops and manufactures the Resorbable Fibrillated Scaffold (RFS), a bioresorbable endovascular implant made from electrospun microfibres with a strutless design. The implant is intended for below-the-knee arteries in patients with chronic limb-threatening ischemia (CLTI), where it provides temporary structural support before gradually dissolving while facilitating native tissue regeneration. The company sells the device to hospitals and vascular specialists for use in treating peripheral artery disease and preventing limb amputation.

Product overview

STENTiT is a medical technology company developing a single core product: the Resorbable Fibrillated Scaffold (RFS). This regenerative endovascular implant is designed specifically for below-the-knee peripheral artery disease treatment, offering a bioresorbable alternative to traditional metal stents. The scaffold provides temporary mechanical support and dissolves over time while promoting tissue regeneration, aiming to prevent amputations in patients with chronic limb-threatening ischemia.

Differentiator

Problem solved

Functional benefit

Products and services

• Resorbable Fibrillated Scaffold (RFS) A bioresorbable, strutless endovascular scaffold manufactured from electrospun microfibres, designed to provide temporary structural support to below-the-knee arteries in patients with chronic limb-threatening ischemia (CLTI) before gradually dissolving while facilitating native tissue regeneration, with the aim of preventing limb amputation. It is intended for use by vascular surgeons and interventional cardiologists in hospitals and vascular surgery centers.

Quantifiable outcome

• 100% technical success rate across first five human implantations in VITAL-IT 1 study
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Medical University of GrazcoreStrategic or Co-development PartnerResearchers at the Medical University of Graz, Austria conducted the VITAL-IT 1 study, performing the first five human implantations of StentIt's resorbable fibrillated scaffold for below-the-knee chronic limb-threatening ischemia. This represents a clinical research partnership for product validation.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Boston Scientific: Major peripheral vascular device incumbent with drug-eluting technologies (Eluvia) and established relationships with the vascular specialists STENTiT targets.
• Medtronic: Global peripheral and coronary device incumbent with deep clinical-trial capacity and a full endovascular product portfolio overlapping with STENTiT's indication.
• Terumo: Japanese medical device major with peripheral vascular and interventional cardiology products, including bioresorbable-adjacent technologies that compete for the same vascular specialists.
• Abbott: Global peripheral vascular leader (e.g., XIENCE, Esprit, Xact) and the developer of the Absorb bioresorbable vascular scaffold; sets the clinical and competitive benchmark STENTiT must overcome.

Direct peers

• Biotronik: European cardiovascular device company with a bioresorbable magnesium scaffold (Magmaris) and a strong peripheral vascular portfolio, making it the closest large-scale direct peer to STENTiT's bioresorbable scaffold strategy.

Emerging players

• Elixir Medical: Developer of bioresorbable scaffold and drug-eluting stent technologies (e.g., DESolve), competing directly in the regenerative endovascular implant category.
• Reva Medical: Developer of the Fantom bioresorbable scaffold; a small-cap peer that has navigated regulatory and commercial headwinds in the same bioresorbable vascular space as STENTiT.
• Concept Medical: Developer of the MagicTouch sirolimus-coated balloon and stent platform targeting peripheral and coronary vascular disease, with overlapping clinical positioning to STENTiT.

Regional players

• MicroPort Scientific: Chinese cardiovascular device company with peripheral vascular and ortho-vascular product lines, serving Asia-Pacific markets that STENTiT does not currently address.
• LifeTech Scientific: China-based cardiovascular occluder and peripheral interventional device maker whose portfolio overlaps with the BTK and peripheral vascular indications STENTiT addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STENTiT